Based on the overall results of our study, there was no significant statistical difference observed between the group of individuals with breast cancer who used tamoxifen and the control group who underwent regular cytological screening in terms of age, gravida, parity, abortion rates, menopause status, co-morbidity rates, related insulin and steroid usage rates, contraceptive method usage rates, and smoking rates. The gene discussed is INS; the disease is breast cancer.